ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0893

Trajectories of Depressive Symptoms in Systemic Lupus Erythematosus over 7 Years

Seerat Chawla1, Jiandong Su2, Zahi Touma3 and Patricia Katz4, 1University of California Los Angeles, Los Angeles, CA, 2University Health Network, Toronto, ON, Canada, 3University of Toronto, Mississauga, ON, Canada, 4University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2021

Keywords: depression, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Depression remains one of the most frequently observed psychiatric disorders in patients with SLE with a pooled prevalence of 35.0% (95% CI: 29.9%-40.3%). Nevertheless, the trajectory of depression in this population remains uncharacterized. Our aims were to: 1) determine longitudinal trajectories of depressive symptoms in patients with SLE, 2) identify baseline factors that predict a patient’s trajectory of depression.

Methods: Longitudinal data on 763 adults with SLE followed over 7 years from a single center were analyzed. Depressive symptoms were assessed with the Centre for Epidemiologic Studies Depression Scale (CESD) annually in years 2-7 providing 6 waves of observation (wave 2 is the baseline assessment for CESD). Patients with two or more waves of data for CESD were included. Group-based joint trajectory modelling was used to model latent classes. Using only members with latent class posterior probability > 0.8, univariable and multivariable analyses were used to examine baseline factors association with latent classes memberships. The outcomes were the ordinal worse classes of depression represented by latent classes. The assumption of proportionality of the model was checked and satisfied between the four latent classes.

Results: Depressive symptoms were mapped into four trajectories: 1) lowest CESD scores (no depression, 36%), 2) low CESD scores (no depression, 32%), 3) high CESD scores (depression, 22%), and 4) highest CESD scores (depression, 10%). Figure 1 shows the longitudinal trajectories of four latent classes based on their CESD values over 7 years.

Table 1 shows the baseline demographic information in four classes of patients after they were grouped into four trajectories.

Data on 584 (76%) patients satisfied the posterior probability 0.8 and were analyzed in the ordinal logistic regression. In the multivariable analyses, older age at baseline, Caucasian, higher education level and less SF-36 Bodily Pain were associated with better CESD classes while higher fatigue score and SLE disease activity by SLAQ were associated with worse CESD classes (Table 2).

Conclusion: Four distinct trajectories for depressive symptoms were found. Baseline factors that were associated with latent classes were identified that may be helpful in identifying individuals with SLE who are at the greatest risk of developing persistent depressive symptoms over time. These results will serve as a more comprehensive guide for prognosis and clinical decisions to improve overall treatment outcomes.

Class 1) lowest CESD scores (no depression, 36%), Class 2) low CESD scores (no depression, 32%), Class 3) high CESD scores (depression, 22%), and Class 4) highest CESD scores (depression, 10%)


Disclosures: S. Chawla, None; J. Su, None; Z. Touma, AbbVie Inc, 2, UCB Biopharma SRL, 2, Sarkana Pharma Inc., 1, 4, Janssen Inc., 2, GlaxoSmithKline Inc., 6; P. Katz, None.

To cite this abstract in AMA style:

Chawla S, Su J, Touma Z, Katz P. Trajectories of Depressive Symptoms in Systemic Lupus Erythematosus over 7 Years [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/trajectories-of-depressive-symptoms-in-systemic-lupus-erythematosus-over-7-years/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trajectories-of-depressive-symptoms-in-systemic-lupus-erythematosus-over-7-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology